Evidence map›Paper›PMID 29936884›Full record

ArticleTissue engineering. Part A2018

Human and Rat Bone Marrow-Derived Mesenchymal Stem Cells Differ in Their Response to Fibroblast Growth Factor and Platelet-Derived Growth Factor.

Donald Lennon, Luis A Solchaga, Rodrigo A Somoza, Mark D Schluchter, Seunghee Margevicius, Arnold I Caplan

Abstract read
In one paragraph

Article in Tissue engineering. Part A, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Donald Lennon1 Department of Biology, Skeletal Research Center, Case Western Reserve University, Cleveland, Ohio.
Luis A Solchaga1 Department of Biology, Skeletal Research Center, Case Western Reserve University, Cleveland, Ohio.
Rodrigo A Somoza1 Department of Biology, Skeletal Research Center, Case Western Reserve University, Cleveland, Ohio.
Mark D Schluchter2 Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Seunghee Margevicius2 Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Arnold I Caplan1 Department of Biology, Skeletal Research Center, Case Western Reserve University, Cleveland, Ohio.
Case Western Reserve University · USUniversity School · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
TR&D-4: Growing Tissue in the Scalable, Modular, Automated, and Closed (SMAC) FoundryP41EB021911 · NIBIB · CASE WESTERN RESERVE UNIVERSITY · PI JEAN F WELTER · 2016 to 2026
$13.9M
CWRU Center for Multimodal Evaluation of Engineered CartilageR01EB020367 · NIBIB · CASE WESTERN RESERVE UNIVERSITY · PI CAPLAN, ARNOLD IRWIN · 2014 to 2015
$807k
NCI NIH HHS P30 CA043703NIBIB NIH HHS P41 EB021911NIBIB NIH HHS R01 EB020367
6 · The paper itself

Abstract

Tissue engineering requires large numbers of cells with enhanced differentiation properties. Thus, the effect of expansion conditions must be explored. Human and rat marrow-derived mesenchymal stem cells (hMSCs and rMSCs, respectively) were comparatively culture expanded through seven passages in the presence of either fibroblast growth factor-2 (FGF-2) or platelet-derived growth factor BB (PDGF-BB). Proliferation of both hMSCs and rMSCs was enhanced by FGF-2 and PDGF-BB. Population doubling times for hMSCs were 2.4 days for control and 1.75 and 2.0 days for FGF-2 and PDGF-BB, respectively, and 3.25, 3.06, and 2.95 days for rMSCs. Supplementation with FGF-2 during cell expansion resulted in significantly greater in vivo bone formation for hMSCs. Use of PDGF-BB resulted in greater bone formation than that observed for control conditions, but the differences were only significant for P1. For rMSCs, significant increases in bone formation were noted in either FGF-2 or PDGF-BB expanded cells implanted at P4 or P7, but not for P1. Under in vitro osteogenic stimulation, calcium content was elevated and bone matrix deposition was enhanced for P1 and P7 rMSCs expanded with FGF-2. Although culture conditions, including FBS, were held constant, these observations suggest that medium must be optimized separately for each species of MSCs.

Indexed as

AnimalsBecaplerminBone Marrow CellsCell ProliferationFibroblast Growth Factor 2HumansMesenchymal Stem CellsOsteogenesisRatsSpecies SpecificityBecaplerminFibroblast Growth Factor 2FGF-2mesenchymal stem cellsPDGF-BB

Identifiers

PMID29936884
PMCPMC6302675
OpenAlexW2811399669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.